Medexus Pharmaceuticals Inc. (TSE:MDP – Get Rating) – Investment analysts at Raymond James reduced their Q2 2023 earnings per share (EPS) estimates for shares of Medexus Pharmaceuticals in a report released on Monday, September 19th. Raymond James analyst R. Sarugaser now forecasts that the company will post earnings of ($0.16) per share for the quarter, down from their prior forecast of ($0.13). The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.05 per share. Raymond James also issued estimates for Medexus Pharmaceuticals’ Q3 2023 earnings at ($0.12) EPS, Q4 2023 earnings at ($0.12) EPS, FY2023 earnings at ($0.49) EPS, Q1 2024 earnings at ($0.20) EPS, Q2 2024 earnings at ($0.20) EPS, Q3 2024 earnings at ($0.19) EPS, Q4 2024 earnings at ($0.19) EPS, FY2024 earnings at ($0.77) EPS and FY2025 earnings at ($0.48) EPS.
Medexus Pharmaceuticals (TSE:MDP – Get Rating) last released its quarterly earnings data on Wednesday, June 22nd. The company reported C($0.29) earnings per share for the quarter, beating the consensus estimate of C($0.40) by C$0.11. The firm had revenue of C$25.67 million during the quarter, compared to the consensus estimate of C$21.69 million.
Medexus Pharmaceuticals Stock Down 4.3 %
Shares of Medexus Pharmaceuticals stock opened at C$1.10 on Thursday. The company has a debt-to-equity ratio of 327.43, a current ratio of 0.97 and a quick ratio of 0.44. The stock has a market cap of C$21.95 million and a price-to-earnings ratio of 6.88. The firm’s 50-day moving average is C$2.32 and its two-hundred day moving average is C$2.52. Medexus Pharmaceuticals has a 1 year low of C$1.05 and a 1 year high of C$3.86.
About Medexus Pharmaceuticals
Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. It focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, and allergy. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, a prescription allergy medication.
- The Institutions Hold On To Darden Restaurants International
- What Steelcase’s Earnings Say About the Return to the Office?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Is The Golden Age Of Homebuilding Already Over?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for Medexus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medexus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.